GLORIA Triumphs at BIO International Convention, Signs Five International Industry-Academia Cooperation Agreements
HOT NEWS GLORIA Triumphs at BIO International Convention, Signs Five International Industry-Academia Cooperation Agreements

Global Research and Industry Alliance (GLORIA) launched by Ministry of Science and Technology  (MoST) joins Taiwan’s biomedical industry delegation led by Minister without Portfolio Wu Tsung-tsong, Executive Yuan, which gathers all 12 alliances to showcase 40 technologies across all biomedical fields, including treatment, smart medical care, and genome editing, at the 2019 BIO International Convention held in Philadelphia, U.S., from June 3 to 6, promoting and showcasing Taiwan’s top-tier academic and industrial energy of the biomedical industry to the world. 

 

GLORIA has achieved fruitful results at this year’s BIO International Convention in terms of international cooperation, signing agreements with international companies from Singapore, the US, and Canada—National Chung Hsing University’s GLORIA signed a MOU with Novotech Nutraceuticals Inc., National Taiwan Ocean University signed a LOI of international membership with Canada’s Industrial Plankton, and Taipei Medical University signed a MOU with AMU Biosciences. Also, after participating in last year’s BIO International Convention in Boston with team GLORIA, Associate Professor Ueng-cheng Yang contacted with L7informatics, Inc. at the convention, and NYMU-GLORIA continued to explore collaborative opportunities, successfully facilitating joint R&D. This year, the two sides returned to BIO International Convention to sign official collaboration agreement to develop clinical ESP in compliance with ECRIN standards.

 

GLORIA teams will also be featured at many international forums, such as the Global Biotech Entrepreneur Taiwan Forum held at Temple University, Pennsylvania, on June 2, which will be attended by industry, academia, and venture capital of Taiwan, U.S., and Italy. Goldsitron led by Professor Tse-ying Liu of National Yang-Ming University will present the newly-developed TSER (Targeted sensitization enhanced radiotherapy) for cancer treatment, and the team at Taipei Medical University led by Associate Professor Kuo-hsiang Chuang will also present their Novel Bispecific-Antibody (BsAb)-Based Culture Platform Technology for Tumor-Specific T Cells, showcasing Taiwan’s achievements in academic research. Furthermore, a delegation of 7 GLORIA biomedical startups led by Deputy Minister Hsieh Dar-bin of Science and Technology will also be engaged in business matching and exchange activities with U.S.’s leading international biomedical accelerator, SmartLabs, on June 4, which includes the AHEAD team from National Taiwan University, the Alpha6GABA team led by Professor Lih-chu Chiou, the IBS new drug team led by Professor Ling-Wei Hsin, startup EverVast of National Taiwan Ocean University, aiming to connect international and domestic startup resources and investments and explore new horizons for Taiwan’s biomedical industry. In the future, SmartLabs will also enter Hsinchu Biomedical Science Park through MoST’s “Biomedical Innovation Cluster Promotion Project.” Furthermore, Riche Bio and MediVisionTech, two startups sprung from National Cheng Kung University’s GLORIA, have both made the top 30 shortlist at the RESI Innovation Challenge, garnering interests from venture capitalists around the world. 

 

This is the second time GLORIA join forces to attend BIO International Convention; this is the biggest delegation ever, featuring 12 alliances and over 40 technologies, including Thermoresponsive Nanobrush Surface Enabling Continuous Harvest of Stem Cells  presented by Professor Akon Higuchi of National Central University, Bioinspired Zwitterionic Technology Platform of Research and Development Center for Membrane Technology, Chung Yuan Christian University, the SHJ002 eye drop for nearsightedness developed by Professor Suh-hang Juo and Dr. Chung-ling Liang of China Medical University, the Innovative Immunosensor for Early Detection to Pancreatic Cancer developed by Professor Congo Tak-Shing Cheng at National Chung Hsing University, AHEAD (AI-assisted Hematologic Analytic and Decision Support) developed by the team led by Dr. Bor-sheng Ko at National Taiwan University, the Universal Microbubbles Based Combined Medical Device for Promoting Local Drug Delivery developed by Professor Ai-ho Liao of National Taiwan University of Science and Technology, National Cheng Kung University’s Riche Bio’s Sample Preparation Free Portable Molecular Testing System, the fluorescent detective system developed by I-Shou University’s GLORIA team led by Professor Li-fen Liu and Professor Chao-yen Wu, Lipoplex novel oral delivery system for economic animals developed by Dr. Ming-wei Lu at National Taiwan Ocean University, and JelloX 3D Imaging Technology developed by startup Jello X led by Professor Yen-yin Lin of National Tsing Hua University, boasting an impressive lineup. 

 

Through the collective effort of GLORIA, MoST has successfully promoted Taiwan’s biomedical research energy and GLORIA services on the grand stage of BIO International Convention, deepening Taiwan’s business connection with the international market.

本網站使用您的Cookie於優化網站及您的瀏覽經驗。繼續瀏覽網站即表示您同意本公司隱私權政策,您可至隱私權政策了解詳細資訊。